Navigation Links
Bone Drugs Not Linked to Rare Fractures
Date:5/12/2010

Small study did not find significant effect with use of bisphosphonates

WEDNESDAY, May 12 (HealthDay News) -- A new study finds no association between the use of a popular class of osteoporosis medications known as bisphosphonates and an unusual type of thigh bone fracture.

Bisphosphonates include blockbuster drugs such as alendronate (Fosamax), risedronate (Actonel) and ibandronate (Boniva).

The conclusions, appearing as a letter-to-the-editor in the May 13 issue of the New England Journal of Medicine, do little to settle an ongoing debate about whether or not these drugs cause this type of rare fracture.

A pharmaceutical-company sponsored study published in March in the same journal concluded that bisphosphonates did not boost people's risk for this type of fracture, although prior studies had suggested they did.

That "very large study," said Dr. Kenneth A. Egol, chief of the Orthopaedic Trauma Service at New York University Hospital for Joint Diseases, "certainly can allay some fears regarding the drug."

And the current study, which is much smaller, should not raise fears or affect how bisphosphonates are used, experts said.

"We believe these are good drugs in the right patient, and there's no reason they should not be used," Egol said.

"We cannot conclude that there's major enough of a side effect that we should be telling patients not to take the medications, and that's consistent with what the FDA [U.S. Food and Drug Administration] is saying," agreed Yuen Ting (Cathy) Lau, an assistant professor of pharmacy practice at Texas A&M Health Science Center Irma Lerma Rangel College of Pharmacy in Houston. "There's no conclusive evidence saying that atypical bone fractures are associated with bisphosphonates and, given the benefits, patients should not stop taking them just because of this concern."

Having said that, Egol did point out that "those who take care of patients with fractures have definitely been seeing this atypical type of femur [thigh] fracture in a subset of, but not all, patients who have been on medication for a long period of time."

The next step, he said, would be to figure out which subset of patients may be at heightened risk for the breaks.

The authors of the study, from the University of Sydney in Australia, reviewed records on 152 femoral fractures in 152 patients between 2003 and 2008. Most of the patients were women, with a mean age of 78.

Seventeen of 20 patients who had one of these unusual fractures were taking bisphosphonates (15 were taking Fosamax for an average of five years and two were taking Actonel for about three years).

Two patients who had not had such fractures were taking Fosamax and one was taking Actonel.

There were also other risk factors associated with the type of fracture, such as steroid treatment for more than six months or having rheumatoid arthritis.

More information

Learn more about osteoporosis medications at the National Osteoporosis Foundation.



SOURCES: Kenneth A. Egol, M.D., chief, orthopaedic trauma service, New York University (NYU) Hospital for Joint Diseases, and professor, orthopaedic surgery, NYU Langone School of Medicine, New York City; Yuen Ting (Cathy) Lau, Pharm.D., assistant professor, pharmacy practice, Texas A&M Health Science Center Irma Lerma Rangel College of Pharmacy, Houston; May 13, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Impotence Drugs May Aid Brain Tumor Treatment
2. Monitoring and control can limit side effects of promising cancer drugs
3. Parkinsons Drugs Tied to Compulsive Behaviors
4. Stomach Acid Drugs Come with Dangers, Studies Show
5. Anemia Drugs Hold Dangers for Kidney Patients
6. As FDA Eyes Prostate Cancer Drugs, Experts Urge Caution
7. Taking Flu Drugs While Pregnant Appears to Be Safe: Study
8. OTC Drugs May Work Differently in Obese Kids
9. Study finds that drugs used for treatment of influenza in pregnancy appear to be safe
10. BATTLE links potential biomarkers to drugs for lung cancer
11. Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: